Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

B D Curti

Showing results (21-30 of 26) with videos related to

Pageof 3
Sort By:
You have reached the last page of results.This site can display upto 26 results.
Blood|May 11, 1999
Abrogation of the hematological and biological activities of the interleukin-3/granulocyte-macrophage colony-stimulating factor fusion protein PIXY321 by neutralizing anti-PIXY321 antibodies in cancer patients receiving high-dose carboplatinL L Miller, E L Korn, D S Stevens, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|August 15, 1998
Phase I trial of anti-CD3-stimulated CD4+ T cells, infusional interleukin-2, and cyclophosphamide in patients with advanced cancerB D Curti, A C Ochoa, G C Powers, et al.
Journal of Immunotherapy with Emphasis on Tumor Immunology : Official Journal of the Society for Biological Therapy|July 1, 1996
Influence of interleukin-2 regimens on circulating populations of lymphocytes after adoptive transfer of anti-CD3-stimulated T cells: results from a phase I trial in cancer patientsB D Curti, A C Ochoa, W J Urba, et al.
Journal of the National Cancer Institute|January 3, 1996
Phase II trial of interleukin 1 alpha and indomethacin in treatment of metastatic melanomaJ E Janik, L L Miller, D L Longo, et al.
Journal of Immunotherapy with Emphasis on Tumor Immunology : Official Journal of the Society for Biological Therapy|September 1, 1996
A phase I randomized study of subcutaneous adjuvant IL-2 in combination with an autologous tumor vaccine in patients with advanced renal cell carcinomaR G Fenton, R G Steis, K Madara, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|May 20, 2026
Five-Year Survival with Tebentafusp in Metastatic Uveal MelanomaS Piperno-Neumann, P Rutkowski, J C Hassel, et al.
Pageof 3

Showing results (21-30 of 26) with videos related to

Sort By:
Pageof 3
You have reached the last page of results.This site can display upto 26 results.
Blood|May 11, 1999
Abrogation of the hematological and biological activities of the interleukin-3/granulocyte-macrophage colony-stimulating factor fusion protein PIXY321 by neutralizing anti-PIXY321 antibodies in cancer patients receiving high-dose carboplatinL L Miller, E L Korn, D S Stevens, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|August 15, 1998
Phase I trial of anti-CD3-stimulated CD4+ T cells, infusional interleukin-2, and cyclophosphamide in patients with advanced cancerB D Curti, A C Ochoa, G C Powers, et al.
Journal of Immunotherapy with Emphasis on Tumor Immunology : Official Journal of the Society for Biological Therapy|July 1, 1996
Influence of interleukin-2 regimens on circulating populations of lymphocytes after adoptive transfer of anti-CD3-stimulated T cells: results from a phase I trial in cancer patientsB D Curti, A C Ochoa, W J Urba, et al.
Journal of the National Cancer Institute|January 3, 1996
Phase II trial of interleukin 1 alpha and indomethacin in treatment of metastatic melanomaJ E Janik, L L Miller, D L Longo, et al.
Journal of Immunotherapy with Emphasis on Tumor Immunology : Official Journal of the Society for Biological Therapy|September 1, 1996
A phase I randomized study of subcutaneous adjuvant IL-2 in combination with an autologous tumor vaccine in patients with advanced renal cell carcinomaR G Fenton, R G Steis, K Madara, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|May 20, 2026
Five-Year Survival with Tebentafusp in Metastatic Uveal MelanomaS Piperno-Neumann, P Rutkowski, J C Hassel, et al.
Pageof 3